Eupraxia Pharmaceuticals Inc Ordinary Shares EPRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
Trading Information
- Previous Close Price
- $6.60
- Day Range
- $6.56–6.68
- 52-Week Range
- $5.30–9.20
- Bid/Ask
- $6.60 / $6.67
- Shares Outstanding
- 66.07M
- Market Cap
- $437.41M
- Volume/Avg
- 2,646 / 654,740
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 49
Valuation
Metric | EPRX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.25 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | EPRX |
|---|---|
Quick Ratio | 15.71 |
Current Ratio | 16.00 |
Interest Coverage | — |
Quick Ratio
EPRX
Profitability
Metric | EPRX |
|---|---|
Return on Assets (Normalized) | −44.47% |
Return on Equity (Normalized) | −69.63% |
Return on Invested Capital (Normalized) | −50.18% |
Return on Assets
EPRX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|^dXXp?# | LOCK|NRy@ | $138B | |||
| Moderna Inc MRNA | LOCK|#f>q@% | LOCK|q@j | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|%vJK<kW | LOCK|D>Fcj | $93B | |||
| argenx SE ADR ARGX | LOCK|Wk>?qw | LOCK|X& | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|y&H!LG% | LOCK|%N< | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|D%XqB&! | LOCK|>G%#r | $30B | |||
| Incyte Corp INCY | LOCK|W@kpXz | LOCK|Wp> | $24B | |||
| BioNTech SE ADR BNTX | LOCK|<&@D&$ | LOCK|<M | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|@wF#J# | LOCK|V?lt | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|<rrCr> | LOCK|S& | $15B |
United States